Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis

被引：0
作者：
James Yarmolinsky
Emmanouil Bouras
Andrei Constantinescu
Kimberley Burrows
Caroline J. Bull
Emma E. Vincent
Richard M. Martin
Olympia Dimopoulou
Sarah J. Lewis
Victor Moreno
Marijana Vujkovic
Kyong-Mi Chang
Benjamin F. Voight
Philip S. Tsao
Marc J. Gunter
Jochen Hampe
Andrew J. Pellatt
Paul D. P. Pharoah
Robert E. Schoen
Steven Gallinger
Mark A. Jenkins
Rish K. Pai
Dipender Gill
Kostas K. Tsilidis
机构：
[1] University of Bristol,MRC Integrative Epidemiology Unit
[2] Bristol Medical School,Population Health Sciences
[3] University of Bristol,Department of Hygiene and Epidemiology
[4] University of Ioannina Medical School,School of Translational Health Sciences
[5] University of Bristol,NIHR Bristol Biomedical Research Centre
[6] University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol,Biomarkers and Susceptibility Unit, Oncology Data Analytics Program
[7] Catalan Institute of Oncology (ICO),Colorectal Cancer Group, ONCOBELL Program
[8] L’Hospitalet de Llobregat,Department of Clinical Sciences, Faculty of Medicine
[9] Bellvitge Biomedical Research Institute (IDIBELL),Department of Medicine
[10] L’Hospitalet de Llobregat,Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine
[11] Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP),Department of Genetics
[12] University of Barcelona,Institute of Translational Medicine and Therapeutics
[13] Corporal Michael J. Crescenz VA Medical Center,Department of Medicine
[14] University of Pennsylvania Perelman School of Medicine,Stanford Cardiovascular Institute
[15] University of Pennsylvania,Nutrition and Metabolism Section, International Agency for Research on Cancer
[16] Perelman School of Medicine,Department of Medicine I
[17] University of Pennsylvania,Department of Public Health and Primary Care
[18] University of Pennsylvania,Department of Medicine and Epidemiology
[19] VA Palo Alto Epidemiology Research and Information Center for Genomics,Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital
[20] VA Palo Alto Health Care System,Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health
[21] Stanford University School of Medicine,Department of Laboratory Medicine and Pathology
[22] Stanford University School of Medicine,Department of Epidemiology and Biostatistics, School of Public Health
[23] World Health Organization,undefined
[24] University Hospital Dresden,undefined
[25] Technische Universität Dresden (TU Dresden),undefined
[26] University of Texas MD Anderson Cancer Center,undefined
[27] University of Cambridge,undefined
[28] University of Pittsburgh Medical Center,undefined
[29] University of Toronto,undefined
[30] The University of Melbourne,undefined
[31] Mayo Clinic Arizona,undefined
[32] Imperial College London,undefined
[33] St Mary’s Campus,undefined
来源：
Diabetologia | 2023年 / 66卷
关键词：
ABCC8; Breast cancer; Colorectal cancer; GLP1R; Glucose-lowering drug targets; Mendelian randomisation; PPARG; Prostate cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1481 / 1500
页数：19
相关论文
共 165 条
  • [21] Ahmad I(2003)Approaches to combat with confounding by indication in observational studies of intended drug effects Pharmacoepidemiol Drug Saf 12 551-351
  • [22] Mui E(2019)Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials Diabetes Obes Metab 21 1871-94
  • [23] Galbraith L(2020)Do GLP-1 receptor agonists increase the risk of breast cancer? A systematic review and meta-analysis J Clin Endocrinol Metab 106 912-87
  • [24] Ferguson RD(2018)causal inference in cancer epidemiology: what is the role of Mendelian randomization? Cancer Epidemiol Biomarkers Prev 27 995-936
  • [25] Novosyadlyy R(2013)Developing a Weibull model extension to estimate cancer latency ISRN Epidemiol 2013 750857-691
  • [26] Fierz Y(2014)Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study J Clin Pharm Ther 39 354-74
  • [27] Wu X(2022)Differential risk of cancer associated with glucagon-like peptide-1 receptor agonists: analysis of real-world databases Endocr Res 47 18-96
  • [28] Fan Z(2010)Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry Diabetes Res Clin Pract 90 343-1418
  • [29] Masui H(2017)Association analysis identifies 65 new breast cancer risk loci Nature 551 92-1184
  • [30] Rosen N(2019)Discovery of common and rare genetic risk variants for colorectal cancer Nat Genet 51 76-532
12345678910